Multiple myeloma
KPTIKaryopharm TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for XPOVIO (Selinexor) (XPO1 inhibitor) + pomalidomide + dexamethasone in Multiple myeloma. The expected timing is based on the latest available company guidance and may change.
05/14/26:- XPORT-MM-031 follow-up continues; top-line data still expected H2 2026. 08/13/26:- XPORT-MM-031 follow-up continues; topline data will be announced in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.